Vivos Therapeutics shares are trading higher after the company announced it received FDA 510(k) clearance for treating severe obstructive sleep apnea in adults using the Vivos' removable CARE oral appliances.
Portfolio Pulse from Benzinga Newsdesk
Vivos Therapeutics' stock is trading higher following the FDA 510(k) clearance for its CARE oral appliances, designed to treat severe obstructive sleep apnea in adults.
November 29, 2023 | 4:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vivos Therapeutics received FDA 510(k) clearance for its CARE oral appliances, which is likely to boost investor confidence and potentially increase sales.
The FDA clearance is a significant regulatory milestone that can lead to increased adoption and sales of Vivos' CARE oral appliances. This approval is likely to be viewed positively by investors, as it opens up market opportunities and validates the company's product, potentially leading to a short-term increase in the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100